

Since joining the CNRS in 1997, Christian CHABBERT has devoted most of his research activity to studying how the vestibule, within our inner ear, shapes vestibular sensory information and how this process can be disrupted in certain pathological situations. He has used in vitro approaches to identify the different mechanisms involved in the control of endolymph ionic homeostasis and neurotransmission at primary vestibular synapses. He has developed various animal models of vestibular pathologies encountered in humans. These models allowed evaluating the benefits of various compounds in the attenuation of acute vertigo caused by excitotoxic or ototoxic vestibular lesions, and in the protection of vestibular synapses. Dr. CHABBERT is considered one of the leading world experts on vestibular plasticity mechanisms. He is the author of more than 90 scientific and clinical publications and has given more than 70 communications at conferences, including 40 international ones. He has supervised 10 doctoral theses. The E-Motion research project he is leading received the IRP (International Research Project) label from the CNRS in December 2024. Since 2015, Dr. CHABBERT has been director of the GDR Vertige (Unit GDR2074 CNRS; <http://gdrvertige.com>), a national federating group bringing together scientists, clinicians and industrialists involved in research on balance disorders and vertigo. He is leading the IREV (Institut de Recherche Équilibre et Vertige) project. Dr CHABBERT also founded Sensorion-Pharmaceuticals and VERTIDIAG, two biotechnology companies dedicated to the development of therapeutic solutions for vestibular disorders. Sensorion went public in 2015 and had a market capitalization of €230 million at the end of 2024. In 2016, he received the grand prize of the Japanese Society for Balance Research. He was associate editor of JARO (1st journal of ear physio & patho research) from 2012 to 2015.